Search

everythinglearnresearchcommunity

for

Search:↓

Hormonal imbalances during menopause may significantly contribute to Frontal Fibrosing Alopecia.

Men and women experience skin aging differently due to changes in sex hormone levels with age.

A woman's adrenal tumor disappeared after treatment with cyproterone acetate.

A woman with Sheehan syndrome improved with hormone treatment.

Over-the-counter products can help with menopause symptoms, but be aware of their ingredients.

Frontal fibrosing alopecia in Brazil mostly affects postmenopausal women, often linked with hypothyroidism and eyebrow hair loss.

PRP injections effectively improve stress urinary incontinence in women.

Women generally handle heart enlargement better than men, but it's riskier for them if it occurs; hormones like estrogen offer some protection.

Women with polycystic ovary syndrome have a higher risk of certain fractures.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting older women, with no known cause and treatments that may help stabilize hair loss.

Women with the NIH type of PCOS have more obesity and higher risk of diabetes and heart disease than those with other types of PCOS.

Thorough evaluation and surgery are crucial for managing rare ovarian tumors in postmenopausal women with high androgen levels.

Flibanserin's effectiveness for low sexual desire in premenopausal women may vary based on hormone levels, with normal hormone levels showing better responses.

Women with PCOS have a similar chance of getting pregnant using assisted reproductive treatment as those without PCOS.

Women with aging signs and heart issues have higher hair loss risk, which may predict shorter lifespan and affect attractiveness.

Hair growth slows and shedding increases after childbirth, but most women don't experience excessive hair loss.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Low-dose ethinyl estradiol and LNG-IUD are safer contraception options for obese women with PCOS.

Testosterone therapy can improve sexual function in women but long-term safety is unclear.

High testosterone increases heart disease risk in women with PCOS.

Androgen therapy can help with symptoms like low libido in women, but more research is needed to understand its long-term safety and effects on health.

Skin and hair aging involves mitochondrial issues, telomere shortening, and hormonal changes, with iron affecting hair loss in pre-menopausal women.

PCOS increases the risk of heart disease and type 2 diabetes in women.

Frontal fibrosing alopecia causes hairline recession and eyebrow loss in postmenopausal women.

The document concludes that breast pain should be managed with personalized treatment, starting with non-drug methods and progressing to medication if necessary, while considering side effects and patient needs.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

GnRH analogues are effective for diagnosing and treating female androgen excess, offering a non-surgical option.

Doctors recommend postoperative radiation for male breast cancer, advise against testosterone for vasomotor symptoms post-adrenalectomy, suggest non-hormonal treatments for atrophic vaginitis after mastectomy, note no specific treatment for anticoagulant-induced hair loss, and call for more research on silicosis from silicon carbide exposure.

Biochemical markers help diagnose ovarian tumors in postmenopausal women.